Synthetic Biologics, Inc.: insider trades · United States · SEC (Form 4)

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. is a U.S.-listed biopharmaceutical company trading in the United States on a NYSE/NASDAQ market venue, and its profile is best understood as that of a small-cap, research-driven biotech rather than a commercial-stage pharmaceutical group. Historically, the company has focused on synthetic biology–inspired therapeutics and, more recently, on microbiome-preserving and enzyme-based approaches intended to address serious gastrointestinal and infectious-disease related needs. For French-speaking investors in France, Belgium, or Switzerland, this is a classic high-risk/high-reward development-stage name: limited current revenues, heavy reliance on clinical progress, licensing opportunities, and capital markets access. ([sec.gov](https://www.sec.gov/Archives/edgar/data/894158/000141057825000285/tmb-20241231x10k.htm?utm_source=openai)) The company’s roots trace back through multiple restructurings, with an operational footprint historically associated with Rockville, Maryland, in the United States. Over time, Synthetic Biologics built its identity around a platform aimed at translating synthetic biology into human therapeutics, before narrowing its emphasis toward the gut microbiome and antibiotic-associated complications. That positioning places it in a specialized competitive set that includes other microbiome-focused biotechs as well as larger pharmaceutical companies that may seek to partner with, license, or acquire differentiated assets. ([theorg.com](https://theorg.com/org/synthetic-biologics?utm_source=openai)) Its core development programs have centered on SYN-004 (ribaxamase), an oral capsule designed to degrade certain IV beta-lactam antibiotics in the gastrointestinal tract to help preserve the normal gut microbiome, and SYN-020, a recombinant oral formulation of intestinal alkaline phosphatase intended for gastrointestinal and systemic disease settings. These candidates reflect a coherent strategy: reduce microbiome disruption, lower downstream infection risk, and target conditions where the biology is compelling but the commercial path depends on proof-of-concept data and partnering. The company therefore competes on scientific differentiation more than on scale, commercial infrastructure, or breadth of marketed products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/894158/000141057825000285/tmb-20241231x10k.htm?utm_source=openai)) From a competitive standpoint, Synthetic Biologics remains a niche developer with a narrow pipeline and a valuation profile that is highly sensitive to clinical readouts, regulatory milestones, and balance-sheet management. Management has highlighted value-creation options such as out-licensing and partnering, which is typical for a company at this stage and is often the most realistic route to monetization in this segment of biotech. Geographically, the business remains predominantly U.S.-centered, though any eventual commercialization of its assets would likely need broader international reach. ([sec.gov](https://www.sec.gov/Archives/edgar/data/894158/000141057825000285/tmb-20241231x10k.htm?utm_source=openai)) Recent developments have underscored the company’s transitional nature: corporate updates, clinical disclosures, and capital-structure actions have remained important themes. In other words, Synthetic Biologics is not yet a broad commercial healthcare platform; it is a U.S. development-stage biotechnology company whose equity story is still tied to pipeline execution, intellectual-property value, and the possibility of strategic transactions. ([syntheticbiologics.com](https://www.syntheticbiologics.com/investors/news/?post_types=press_releases&utm_source=openai))